GR is a unique disease variant of rosacea, characterised by chronic relapsing inflammatory disease with various clinical features such as facial erythema, papules, flushing, pustules, and telangiectasias. Histopathologic findings feature characteristic non-caseated epithelioid granulomas. Little is known about the cell types involved in propagating GR or the underlying signalling that drives this disease. Neurovascular/neuroimmune dysregulation, which includes both anatomic and physiochemical differences present in rosacea-prone skin as compared with healthy facial skin, appears to be a major contributor that exacerbates the vasodilation of facial skin vasculature with increased facial blood flow that occurs during a rosacea flare [2].
Dr Hong and colleagues measured the differences in the expression rate of toll-like receptor 2 (TLR2), neurofilament, and mast cells in ETR (n=12), GR (n=12), and normal skin (n=11). All patients were diagnosed by clinical features and pathology-confirmed biopsies. The researchers performed quantitative analysis of immunohistochemical staining (i.e. number of pixels per image) and found no significant differences in neurofilament staining in any of the groups. GR had significant higher levels of mast cells than either ETR (P<0.05) or the control group (P<0.001); ETR was not significantly higher than the controls. For TLR2 expression, both ETR and GR had significantly higher levels than the control group (P<0.05 for both), although they did not significantly differ from each other.
Mast cells are key effectors in neurogenic inflammation and in rosacea evolution to a chronic stage. Since GR is a later-stage disease than other subtypes, Dr Hong speculated that mast cells may invade when the neurogenic inflammation begins to aggravate. In addition, research supports the observation that TLR2 triggers inflammation by kallikrein 5 (KLK5)-cathelicidin cascade. Increased TLR2 expression may be responsible for abnormal expression of KLK5 and cathelicidin, both of which are important in rosacea. Neurofilament is associated with neurogenic inflammation induced by neuromediators in sensory nerves, but no differences were noted between groups in this study, perhaps due to the sensitivity of the technique used.
The results of this study suggest that the increased expression of mast cell tryptase may be a sign of chronic later-stage GR. Increased expression of TLR2 suggests that cathelicidin-induced neuroimmune pathogenesis also contributes to the pathophysiology of GR. This was a small descriptive study, but it is suggestive that a larger scale immunohistochemical study is needed to confirm results on the pathophysiology of GR.
- Hong E. P007, SPIN 2019, 25-27 April, Paris, France.
- Two AM, Del Rosso JQ. J Clin Aesthet Dermatol. 2014 Jan;7(1):20-5.
Posted on
Previous Article
« Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients Next Article
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis »
« Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients Next Article
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis »
Table of Contents: SPIN 2019
Featured articles
Letter from the Editor
Aetiology: Triggers and Risk Factors
Understanding genetics to unravel psoriasis and atopic dermatitis pathogenesis
Atopic dermatitis and psoriasis: on a spectrum?
Advances in Therapy
Advances in target-oriented therapy: psoriatic arthritis
Favourable safety profile of long-term use of ixekizumab
Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients
Fumarates and vitamin A derivatives advance and latest insights in non-biologic systemic therapeutic agents in psoriasis and atopic dermatitis
Certolizumab: Long-term safety and efficacy results for psoriasis-related nail disease
Novel Considerations
Granulomatous rosacea: exploratory histological markers
Live imaging of cutaneous immune responses
Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?
ABP501 biosimilar for adalimumab: What you need to know
Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Small molecules, apremilast, and TYK2
Related Articles
May 31, 2024
What’s new in clinical dermatology?
February 3, 2022
DLQI scores underestimated during lockdowns?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com